Completed PHASE2 INTERVENTIONAL 2-arm NCT01630811

Nuedexta for the Treatment of Adults With Autism (Nuedexta)

Nuedexta for Neurobehavioral Symptoms of Adults With Autism Spectrum Disorder

Sponsor: Sutter Health

Conditions Autism

Updated 8 times since 2017 Last updated: Nov 4, 2017 Started: Jan 24, 2012 Primary completion: Dec 15, 2015 Completion: Dec 15, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01630811, this PHASE2 trial focuses on Autism and remains completed. Sponsored by Sutter Health, it has been updated 8 times since 2012, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Dec 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 3 earlier versions

May 2017 — Dec 2017 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Feb 2017 — May 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sutter Health

Data source: Sutter Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sacramento, United States